IO Biotech announces data related to IO102-IO103 in combination with KEYTRUDA

IO Biotech (IOBT) announced that data from a pre-defined interim analysis related to the lung cohort of the Phase 2 basket trial with IO102-IO103 in combination with KEYTRUDA, Merck’s (MRK) anti-PD-1 therapy, as first-line therapy were presented today at the IASLC 2023 World Conference on Lung Cancer. Abstract: Ph 2 Trial of IO102-IO103 Vaccine Plus Pembrolizumab: Preliminary Results for the First-line Treatment of Lung Adenocarcinoma. This ongoing Phase 2 trial is enrolling patients with metastatic adenocarcinoma NSCLC with a PD-L1 tumor proportion score greater than or equal to 50% and no prior treatments for metastatic disease. As of the data cut-off in July 2023, 25 patients had been enrolled in the lung cohort of this basket trial. Included in today’s mini-oral presentation is data from the pre-defined interim analysis of the first 15 efficacy-evaluable patients who had received at least 2 full cycles of treatment, and either had at least 2 post-baseline tumor assessments or discontinued. The data show that 8 of these 15 patients, had a confirmed partial response. The median duration of exposure is 15 weeks. The safety profile observed in this study are similar to past studies of IO102-IO103 in combination with pembrolizumab, which have demonstrated a profile consistent with pembrolizumab monotherapy with no noted additional significant systemic toxicity.